Efficacy and safety of vedolizumab in daily clinical practice in patients with inflammatory bowel disease

Abstract:

Vedolizumab is a humanized monoclonal antibody IgG1 that binds to the integrin a4b7 receptors on the intestinal mucosa. Based on the results of GEMINI clinical trials, vedolizumab has been approved for the treatment of patients with moderate and severe active ulcerative colitis (UC) and Crohn‘s disease (CD). Extensive research has been published on the use of vedolizumab in daily clinical practice, evaluating clinical response, clinical and endoscopic remission, remission without use of corticosteroids, need for surgical procedures and hospitalizations, and safety of use. Everyday clinical practice has demonstrated the efficacy of vedolizumab, the results being consistent with data from clinical trials suggesting safe and effective long-term use of vedolizumab.

Key words:
Crohn‘s disease; efficacy; safety; Ulcerative colitis; vedolizumab